This marks the fourth consecutive year that
Castle has earned a MedTech Breakthrough Award for its innovative
testing solutions
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving
health through innovative tests that guide patient care, today
announced that it has been selected as the winner of the “Best
Overall Mental Health Solution” award in the eighth annual MedTech
Breakthrough Awards program for its IDgenetix® pharmacogenomic
(PGx) test. The MedTech Breakthrough Awards honor excellence and
recognize innovation, hard work and success in a range of health
and medical technology categories, attracting thousands of
nominations from over 18 countries across the world.
“Nearly half of all Americans will meet the criteria to be
diagnosed with a mental health condition at some point during their
life,”1 said Derek Maetzold, president and chief executive officer
of Castle Biosciences. “This stark reality underscores the critical
need for advanced tests like IDgenetix that can improve medication
management for those struggling with neuropsychiatric
conditions.”
“By taking into account lifestyle factors and drug-drug
interactions in addition to drug-gene interactions, IDgenetix
provides invaluable information that may impact a patient’s
response to medications,” said Steve Johansson, managing director,
MedTech Breakthrough. “So many patients with major depressive
disorder don’t achieve remission even after trying multiple
medications. Others don't achieve remission until trying four or
more medications, delaying critical relief for those struggling
with the daily challenges of their conditions. IDgenetix is
designed to arm clinicians with personalized health information to
help guide medication selection and management decisions, so
patients can potentially achieve remission from their
neuropsychiatric condition faster.”
“May is Mental Health Month, and receiving this recognition now
makes it even more meaningful, as we strive to improve mental
health care through personalized PGx testing," continued Maetzold.
“We are incredibly honored to have earned a fourth MedTech
Breakthrough Award for our innovative tests designed to improve
patient care.”
Observed each May, Mental Health Month was founded by Mental
Health America (MHA) to promote awareness, provide vital resources
and education, and advocate for the mental health and well-being of
all people living in the United States. Castle is proud to be a
platinum sponsor of MHA in 2024, which marks the 75th year since
the organization launched Mental Health Week, which later evolved
into Mental Health Month.
IDgenetix is Castle Biosciences' advanced precision medicine
test that offers clinicians an objective way to choose or modify
neuropsychiatric medication for their patients with mental health
conditions. By combining pharmacogenomics (PGx) — the practice of
analyzing a patient’s DNA for pharmacogenetic biomarkers that may
influence response to medication — with drug-drug interactions and
lifestyle factor data, IDgenetix can help facilitate a more
informed approach to mental health care in patients suffering from
10 neuropsychiatric conditions. While currently available PGx tests
include information on genetic variants that may affect the
efficacy or side-effect profile of a prescribed medication, Castle
believes IDgenetix offers more by also considering lifestyle
factors and drug-drug interactions. Randomized controlled study
data presented at Psych Congress 2023 showed that integrating
drug-gene, drug-drug and lifestyle factors provides 75% more guided
information compared to traditional drug-gene interactions
alone.2
Castle has previously won three consecutive MedTech Breakthrough
Awards: “Best Use of Artificial Intelligence in Healthcare” in 2023
for its TissueCypher® Barrett's Esophagus test, “Best New
Technology Solution — Dermatology” in 2022 for its
DecisionDx®-Melanoma gene expression profile (GEP) test, and “Best
New Technology Solution — Oncology” in 2021 for its DecisionDx®-SCC
and DiffDx®-Melanoma GEP tests.
About MedTech Breakthrough
Part of Tech Breakthrough, a leading market intelligence and
recognition platform for global technology innovation and
leadership, the MedTech Breakthrough Awards program is devoted to
honoring excellence and innovation in medical & health
technology companies, products, services and people. The MedTech
Breakthrough Awards provide a platform for public recognition
around the achievements of breakthrough healthcare and medical
companies and products in categories that include Patient
Experience & Engagement, Health & Fitness, Medical Devices,
Clinical Administration, Connected Healthcare, Medical Data,
Healthcare Cybersecurity and more. For more information, visit
MedTechBreakthrough.com.
About Mental Health America
Mental Health America (MHA) is the nation's leading national
nonprofit dedicated to the promotion of mental health, well-being
and illness prevention. MHA’s work is informed, designed, and led
by the lived experience of those most affected. Operating
nationally and in communities across the country, MHA advocates for
closing the mental health equity gap while increasing nationwide
awareness and understanding through public education, direct
services, tools and research. MHA’s annual State of Mental Health
in America report is among the most widely respected health reports
in the nation. Visit MHANational.org for more information.
About IDgenetix
IDgenetix is a pharmacogenomic (PGx) test for depression,
anxiety and other mental health conditions designed to analyze a
patient’s genetic make-up to guide timely and evidence-based
decisions on the optimal drug for each patient. IDgenetix is
designed to provide important genetic information to clinicians to
help guide personalized treatment plans for their patients, with
the potential to help patients achieve a faster therapeutic
response and improve their chances of remission by identifying
appropriate medications more efficiently than the standard of care
trial-and-error approach. IDgenetix provides drug-drug and
drug-gene interactions and is supported by a published,
peer-reviewed randomized controlled trial that observed clinical
utility over the standard of care when physicians used IDgenetix
prior to prescribing a medication. IDgenetix is currently
reimbursed by Medicare for the following eight mental health
conditions: major depressive disorder, schizophrenia, bipolar
disorder, anxiety disorders, panic disorder, obsessive-compulsive
personality disorder, post-traumatic stress disorder and attention
deficit hyperactivity disorder.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics
company improving health through innovative tests that guide
patient care. The Company aims to transform disease management by
keeping people first: patients, clinicians, employees and
investors.
Castle’s current portfolio consists of tests for skin cancers,
Barrett’s esophagus, mental health conditions and uveal melanoma.
Additionally, the Company has active research and development
programs for tests in other diseases with high clinical need,
including its test in development to help guide systemic therapy
selection for patients with moderate-to-severe atopic dermatitis,
psoriasis and related conditions. To learn more, please visit
www.CastleBiosciences.com and connect with us on LinkedIn,
Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath
Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM,
DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle
Biosciences, Inc.
- Mental Health America;
https://mhanational.org/mentalhealthfacts; accessed 4/23/24
- The Importance of Incorporating Drug-Drug Interactions and
Lifestyle Factors in Pharmacogenomics-Guided Medication Management
for Patients With Major Depressive Disorder in a Randomized
Controlled Trial;
https://castlebiosciences.com/Scientific%20Evidence/Files/MH_01_002%20Psych%20Congress%20Final%20Upload.pdf
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, which are subject to the “safe harbor” created by those
sections. These forward-looking statements include, but are not
limited to, statements concerning: the ability of IDgenetix to (i)
improve medication management for those struggling with
neuropsychiatric conditions; (ii) provide invaluable information
that may impact a patient’s response to medications; (iii) arm
clinicians with personalized health information to help guide
medication selection and management decisions to help patients
potentially achieve remission from their neuropsychiatric condition
faster; and (iv) help facilitate a more informed approach to mental
health care in patients suffering from 10 neuropsychiatric
conditions. The words “can,” “would” and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. We may
not actually achieve the plans, intentions or expectations
disclosed in our forward-looking statements, and you should not
place undue reliance on our forward-looking statements. Actual
results or events could differ materially from the plans,
intentions and expectations disclosed in the forward-looking
statements that we make. These forward-looking statements involve
risks and uncertainties that could cause our actual results to
differ materially from those in the forward-looking statements,
including, without limitation: subsequent study or trial results
and findings may contradict earlier study or trial results and
findings or may not support the results shown in this study,
including with respect to the discussion of IDgenetix in this press
release; actual application of our IDgenetix test may not provide
the aforementioned benefits to patients; and the risks set forth
under the heading “Risk Factors” in our Annual Report on Form 10-K
for the year ended December 31, 2023, our Quarterly Report on Form
10-Q for the quarter ended March 31, 2024 and in our other filings
with the SEC. The forward-looking statements are applicable only as
of the date on which they are made, and we do not assume any
obligation to update any forward-looking statements, except as may
be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240510837170/en/
Investor Contact: Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact: Allison Marshall
amarshall@castlebiosciences.com
Castle Biosciences (NASDAQ:CSTL)
Historical Stock Chart
From Sep 2024 to Oct 2024
Castle Biosciences (NASDAQ:CSTL)
Historical Stock Chart
From Oct 2023 to Oct 2024